Journal article
Results of a randomized Trial of Chlorambucil versus Fludarabine for patients with untreated Waldenström Macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma
V Leblond, S Johnson, S Chevret, A Copplestone, S Rule, O Tournilhac, JF Seymour, RD Patmore, D Wright, P Morel, MS Dilhuydy, S Willoughby, C Dartigeas, M Malphettes, B Royer, M Ewings, G Pratt, J Lejeune, F Nguyen-Khac, S Choquet Show all
Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2013
Abstract
Purpose: Treatment options for patients with Waldenström macroglobulinemia (WM) and closely related disorders include alkylating agents, purine analogs, and monoclonal antibodies. No large randomized studies have yet been reported comparing any of these approaches. Patients and Methods: The randomized WM1 study (Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia) was undertaken in 101 centers in five countries enrolling 414 eligible patients (339 with WM, 37 with non-mucosa-associated lymphoid tissue marginal zone lymphoma, and 38 with lymphoplasmacytic lymphoma) who were randomly assigned to receive chlorambucil or fludarabine. The primary en..
View full abstractGrants
Funding Acknowledgements
Supported by Schering and Bayer Pharmaceuticals; Genzyme provided fludarabine for French patients; and Schering Health Care supported the United Kingdom Web site.Although all authors completed the disclosure declaration, the following author(s) and/or an author's immediate family member(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a "U" are those for which no compensation was received; those relationships marked with a "C" were compensated. For a detailed description of the disclosure categories, or for more information about ASCO's conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors. Employment or Leadership Position: None Consultant or Advisory Role: Veronique Leblond, Roche (C); Russell D. Patmore, Roche (C); Sylvain Choquet, Roche (C) Stock Ownership: None Honoraria: Veronique Leblond, Janssen-Cilag, Mundipharma; Steve Johnson, Schering Health Care; Olivier Tournilhac, GlaxoSmithKline, Janssen-Cilag, Mundipharma, Roche; Roger G. Owen, Celgene, Ortho Biotech, Roche Research Funding: Veronique Leblond, Genzyme Expert Testimony: None Other Remuneration: None